following a resubmission considered under the end of life and orphan process:
trabectedin (Yondelis®) is not recommended for use within NHSScotland.
Indication under review: for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.
Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.
Trabectedin, compared with an alkylating chemotherapy, increased progression-free survival but not overall survival in patients with advanced liposarcoma or leiomyosarcoma who had previously been treated with an anthracycline-based chemotherapy. The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- trabectedin (Yondelis)
- SMC ID:
- SMC2210
- Indication:
Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.
- Pharmaceutical company
- Immedica
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 09 December 2019